Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA7 | P43166 | 2/20 | 0.54 |
| ▸ | OGA | O60502 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | SLC27A1 | Q6PCB7 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3396176 | 0.89 | MEN1 (0.54) | CA1CA2CA7OGAALDH1A1 | |
| SCHEMBL3391968 | 0.88 | KDM4E (0.60) | CA1CA2CA7OGACA9 | |
| SCHEMBL3393954 | 0.81 | CA1 (0.56) | CA1CA2CA7ALDH1A1MEN1 | |
| SCHEMBL3392183 | 0.79 | CLK1 (0.65) | CA1CA2CA7SLC27A1ALDH1A1 | |
| SCHEMBL3393276 | 0.78 | SLC27A1 (0.74) | CA1CA2CA7SLC27A1ALDH1A1 | |
| SCHEMBL3393148 | 0.78 | SLC27A1 (0.62) | CA1CA2CA7SLC27A1ALDH1A1 | |
| SCHEMBL3394204 | 0.77 | SMN1; SMN2 (0.64) | CA1CA2CA7ALDH1A1KDM4E | |
| SCHEMBL3390183 | 0.73 | MMP2 (0.65) | CA1CA2CA7ALDH1A1KDM4E | |
| SCHEMBL7430239 | 0.73 | CA1 (0.65) | CA1CA2CA7ALDH1A1MEN1 | |
| SCHEMBL3398002 | 0.72 | SLC27A1 (0.62) | CA1CA2CA9SLC27A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029681-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-02-04 | — | — | US | claimed |
| EP-2024364-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2009-02-18 | — | — | EP | claimed |
| WO-2007137417-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-12-06 | — | — | WO | claimed |
| US-20100029681-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-02-04 | — | — | US | disclosed |
| US-20100029681-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-02-04 | — | — | US | disclosed |
| WO-2007137417-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029681-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNA1C, CACNA1I | CA1 313/4885CA2 85/4885CA7 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.